Our position on

Access to medicines and vaccines

• Patents and access to medicines in developing countriesPDF - 188.1KB
• Technology transfer, capacity building and developing countriesPDF - 99.3KB
• Tiered pricing and vaccinesPDF - 150.2KB
• Civil society organisations and vaccine procurementPDF - 152.3KB
• Tackling Global Health ChallengesPDF - 182.8KB
• Compassionate usePDF - 145.9KB
• Product donationsPDF - 85.1KB

Responsible science

• Our Approach to Clinical TrialsPDF - 85.3KB
• Cloning and Stem Cell TechnologiesPDF - 66.9KB
• The convention on biological diversityPDF - 68.3KB
• Public disclosure of clinical researchPDF - 225.3KB
• The care, welfare and treatment of animalsPDF - 68.8KB
• PharmacovigilancePDF - 161.3KB
• Falsified and Substandard Healthcare productsPDF - 165.6KB

Valuing innovation

• Incremental innovationPDF - 52.6KB
• Compulsory licensingPDF - 195.1KB
• EvergreeningPDF - 57.5KB
• A disclosure requirement in patent lawPDF - 74.9KB
• Regulatory data protectionPDF - 72.8KB

Health security

• Pandemic preparednessPDF - 270.4KB
• Combating antimicrobial resistancePDF - 208.8KB

Environment and nature impact

• Hazardous chemicals managementPDF - 64.3KB
• Genetically modified micro-organisms and Environment, Health and Safety (EHS)PDF - 206.0KB
• NanotechnologyPDF - 65.3KB
• Respiratory Products and Global WarmingPDF - 26.2KB
• Pharmaceuticals in environmentPDF - 206.5KB
• The impact of climate change on healthPDF - 54.6KB
• Climate Change and GSK’s OperationsPDF - 196.3KB
• Water stewardshipPDF - 144.2KB
• Deforestation-free sourcingPDF - 156.0KB

Business integrity

• Engagement with patient organisationsPDF - 317.6KB

• Conflict mineralsPDF - 193.7KB

• Competitiveness and investment criteriaPDF - 55.6KB
• Human rightsPDF - 144.6KB
• Marketing practices and scientific engagementPDF - 60.5KB
• Safeguarding personal informationPDF - 196.3KB
• Tax strategyPDF - 260.9KB
• Political AdvocacyPDF - 295.8KB
• Working with third partiesPDF - 252.4KB
• Lethal InjectionsPDF - 79.0KB